A similar response was also shown by Kavuri et al34, where treatment of HER2‐mut CRC cell‐lines with a single HER2‐targeted agent produced delayed tumour growth and treatment with dual agents (anti‐HER2 therapy plus a tyrosine kinase inhibitor) produced tumour regression. Here, ERBB2 is linked to neoplasm.